U.S. markets open in 3 hours 53 minutes

Fortress Biotech, Inc. (FBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5200-0.1300 (-4.91%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.6500
Open2.6000
Bid0.0000 x 2200
Ask2.7000 x 1100
Day's Range2.4417 - 2.6900
52 Week Range1.0400 - 4.7800
Volume917,426
Avg. Volume1,608,690
Market Cap231.73M
Beta (5Y Monthly)2.20
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Fortress Biotech (FBIO) Enters Oversold Territory
    Zacks

    Fortress Biotech (FBIO) Enters Oversold Territory

    Fortress Biotech (FBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Fortress Biotech Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Fortress Biotech Sees Hammer Chart Pattern: Time to Buy?

    Fortress Biotech has been struggling lately, but the selling pressure may be coming to an end soon.

  • Why Fortress Biotech Stock Is Plunging Today
    Motley Fool

    Why Fortress Biotech Stock Is Plunging Today

    Shares of Fortress Biotech (NASDAQ:FBIO), a biopharmaceutical company, were down by 22.5% as of 12:26 p.m. EDT on Monday, after dropping by as much as 28.3% earlier in the day. In December 2019, Avenue Therapeutics submitted an NDA for IV Tramadol for the management of acute pain in patients who require an opioid. The FDA had no complaints regarding the efficacy of the medicine.